TY - JOUR T1 - SARS-CoV-2 antibody seroprevalence in a London HIV clinic cohort JF - Sexually Transmitted Infections JO - Sex Transm Infect DO - 10.1136/sextrans-2021-055306 SP - sextrans-2021-055306 AU - Venkateshwaran Sivaraj AU - Harry Coleman AU - Gaia Nebbia AU - Sam Douthwaite AU - Ranjababu Kulasegaram Y1 - 2022/11/17 UR - http://sti.bmj.com/content/early/2022/11/17/sextrans-2021-055306.abstract N2 - The COVID-19 pandemic started in London during the latter part of January 2020 and reached its peak in April 2020. Antibodies to the SARS-CoV-2 develop 2–3 weeks after exposure and decreases following recovery from illness.1 In the UK, patients accessing the National Health Service were able to request SARS-CoV-2 antibody testing since May 2020. Patients attending our HIV clinic were able to opt-in for SARS-CoV-2 antibody testing during their routine monitoring visit for blood tests. Laboratory tests were used to detect SARS-CoV-2 nucleic acid antibodies in serum samples. A retrospective study was conducted to know the seropositivity rate among the tested cohort of our large central London HIV clinic.We collected data of people living with HIV who opted-in for SARS-CoV-2 antibody test from 1 May 2020 to 31 December 2020. Data on demographics, body mass index (BMI), comorbidities, concomitant medications, Antiretroviral therapy (ART), CD4 count and HIV viral load, symptoms of COVID-19 and hospital admissions were collected for people who tested positive for antibodies. The test result was considered negative when reported as inconclusive.A total of 2567 (65.9%) people opted-in for the SARS-CoV-2 antibody test. Among them, 271 (10.6%) were tested positive; male: … ER -